The Pryor-Cohen letter

The lawmakers appended four questions arising from prior contacts with the company, which Berlex said it intends to answer this week. The questions are not included here because the context is not clear. However, they relate to the amount of drug covered by the price, Berlex's net revenue and profit per patient, the role of pharmacists and the prospects for deferred billing.

Dear Dr. Engel,...